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ABSTRACT
The expression of the catalytic subunit (hTERT)
represents the limiting factor for telomerase activity.
Previously, we detected a transcriptional repressor
effect of the proximal exonic region (first two
exons) of the hTERT gene. To better understand the
mechanism involved and to identify a potential
repressor, we further characterized this region. The
addition of the hTERT proximal exonic region down-
stream of the hTERT minimal promoter strongly
reduced promoter transcriptional activity in all cells
tested (tumor, normal and immortalized). This exonic
region also significantly inhibited the transcriptional
activity of the CMV and CDKN2A promoters, regard-
less of the cell type. Therefore, the repressor effect
of hTERT exonic region is neither cell nor promoter-
dependent. However, the distance between the
promoter and the exonic region can modulate this
repressor effect, suggesting that nucleosome posi-
tioning plays a role in transcriptional repression.
We showed by electrophoretic mobility shift assay
that CCCTC-binding factor (CTCF) binds to the prox-
imal exonic region of hTERT. Chromatin immuno-
precipitaion assays confirmed the binding of CTCF
to this region. CTCF is bound to hTERT in cells
in which hTERT is not expressed, but not in
telomerase-positive ones. Moreover, the transcrip-
tional downregulation of CTCF by RNA interference
derepressed hTERT gene expression in normal
telomerase-negative cells. Our results suggest
that CTCF participates in key cellular mechanisms
underlying immortality by regulating hTERT gene
expression.
INTRODUCTION
Telomeres are specific sequences composed of tandem repeats
of the TTAGGG sequence at the end of human chromosomes
(1). Possible functions of this non-coding DNA include pre-
vention of chromosome degradation, end-to-end fusions,
rearrangements and chromosome loss (2). In normal cells,
each division is associated with telomere shortening (3).
Telomerase is a ribonucleoprotein complex in which the cata-
lytic subunit, hTERT, uses a specific RNA, hTERC, as a tem-
plate for the addition of telomeric repeat sequences to the ends
of chromosomes (4–6). Telomerase activity is detectable dur-
ing embryogenesis in a variety of fetal tissues (7), while in
adult humans, telomerase activity is not detectable in most
somatic cells (8). In contrast, highly proliferative cells, such as
germ cells and stem cells, as well as 85–95% of cancers
express telomerase (9).
The presence of the two major subunits, hTERT and
hTERC, is sufficient to reconstitute telomerase activity
in vitro (10), but additional telomerase-associated proteins
have been identified in vivo (11,12). It has been shown that
expression of hTERT is sufficient to restore telomerase activity
in telomerase-negative cells (13–15). Expression of the hTERT
gene is highly regulated and correlates with telomerase activ-
ity (16,17). The genomic organization of the hTERT gene and
features of its promoter have been described by several groups
and a region encompassing the 283 bp upstream of the trans-
lation site, designated as the core promoter, is essential for
transcriptional activity (18–20). Specific binding sites for
activators and repressors of transcription have been identified
*To whom correspondence should be addressed. Tel: +41 21 314 7153; Fax: +41 21 314 7115; Email: Jean.Benhattar@chuv.hospvd.ch
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors
 The Author 2005. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
6850–6860 Nucleic Acids Research, 2005, Vol. 33, No. 21
doi:10.1093/nar/gki989
in the hTERT promoter sequence (21–35). Additional regulat-
ory elements have been identified distant from the 50 flanking
region of the hTERT promoter (36). Moreover, studies of RNA
processing revealed complex splicing patterns in different cell
types (16) which suggest regulation of hTERT translation by
alternative splicing (37–39).
In telomerase-positive cell lines, the transient transfection
of the hTERT promoter yields a high level of transcriptional
activity, similar to that induced by the SV40 early promoter
(40,41). This is in stark contrast with the low endogenous
hTERT mRNA levels detected in telomerase-positive cell
lines which are as low as 0.2–6 copies/cell (36,42). In transient
transfection assays the proximal exonic region (first two
exons) of the hTERT gene was shown to contain repressor
elements (41). The regulation of hTERT expression, therefore,
appears to be rather complex.
Based upon the published reports we hypothesize that the
proximal exonic region of the hTERT gene plays an important
role in the regulation of hTERT transcription. Conceptually,
this might be due to the distance between the core promoter
and the transcriptional start site and might involve binding of
repressors, as well as histone acetylation. We therefore set out
to explore the effect of the distance between the core promoter
and the transcription start site on hTERT transcription in
telomerase-positive and -negative cells. In addition, we invest-
igated the interaction of CCCTC-binding factor (CTCF), a
ubiquitously expressed 11 zinc finger protein, with the first
exon of the hTERT gene.
MATERIALS AND METHODS
Cell culture
The human tumor cell lines (HeLa, cervical adenocarcinoma;
SW480, colorectal adenocarcinoma; NCCIT, teratocarcinoma;
OVCAR-3, adenocarcinoma of the ovary; and U2-OS, osteo-
sarcoma) and normal human fibroblasts (BJ) were obtained
from ATCC. All cells were grown in the medium recommen-
ded by ATCC. The GM847, HLF and HLF/hTERT cells
were kindly provided by Dr Joachim Lingner (ISREC, Epa-
linges, Switzerland). They were cultured in DMEM supple-
mented with 10% heat inactivated fetal bovine serum
(FBS). The cell lines, HeLa, SW480, NCCIT and OVCAR-
3, are telomerase-positive, whereas the U2-OS cell line is
telomerase-negative. The normal human fibroblasts HLF
and BJ are telomerase-negative. GM847 is an SV40 immor-
talized, but telomerase-negative cell line derived from normal
fibroblasts. HLF/hTERT cells were obtained through stable
transfection of HLF cells with hTERT cDNA construct,
express hTERT and exhibit telomerase activity.
Plasmid construction
pTERT–297 contains the hTERT minimal promoter (41). The
pTERT–297/ex1 vector contains the hTERT minimal promoter
and 80 bp of the first exon. To construct this vector, an hTERT
fragment was generated by PCR and cloned into the pGL3
basic vector (Promega, Madison, WI) opened previously with
SacI and HindIII. The primers used for PCR amplification of
the hTERT fragment also contained the SacI and the HindIII
sites (in bold) and were FW-50-GGCTGCGAGCTC-
CAGGCCGGGCTCCCAGTGGAT-30 (beginning of the
exon1) and REV-50-GGCAAGCTTCGAACGTGGCCAGC-
GGCAGCACCTC-30 (end of the exon1).
A 1804 bp fragment, containing the hygromycine resistance
gene and the FRT site, was deleted by PvuII digestion from the
pcDNA5/FRT vector (Invitrogen, Basel, Switzerland). The
resulting 3266 bp vector was named pcDNA5. The 1983 bp
firefly luciferase sequence was obtained through digestion of
the pGL3 basic vector (Promega, Madison, WI) with NheI and
BamHI and was subcloned into pcDNA5. This new construct
contained the CMV promoter upstream of the firefly luciferase
gene and was named pCMVluc. We further deleted the CMV
promoter from the pCMVluc vector with BglII and NheI, and
inserted two other promoters, hTERT or the CDKN2A pro-
moter amplified by PCR. These constructs were named pTER-
Tluc and pCDKN2Aluc, respectively.
After digestion of the pCMVluc, pTERTluc and
pCDKN2Aluc vectors with NheI and HindIII, the PCR
fragment containing the hTERT proximal exonic region
(first exon and 885 bp of the second exon, without the first
intron) and flanking with the NheI and the HindIII restriction
sites, was subcloned into these vectors to create the pCM-
Vtertluc, the pTERTtertluc and the pCDKN2Atertluc vectors,
respectively.
Three different sequences (44, 100 and 200 bp), which
did not contain motifs with transcriptional interest, were got
from the pcDNA5 vector. These plasmid fragments were gen-
erated by PCR using primers containing the NheI restriction
site: (in bold) 50-GCTGGCGCTAGCTCATAGCTCACGC-
TGTA-30 and 50-GCCTGCTAGCCCTACACCGAACTGA-
GATAC-30 generated the 44 bp insert; 50-TAACGTGC-
TAGCGCGCCTTATCCGGTAACT-30 and 50-GTCGCTA-
GCCTGCTAATCCTGTTACCAGTGGC-30 generated the
100 bp insert; 50-TAACGTGCTAGCGCTTTCTCATAGCT-
CACGCT-30 and 50-GCTGCTAGCCTGCTAATCCTGTT-
ACCAGTGGC-30 generated the 200 bp insert. Then, these
sequences were inserted into the pCMVtertluc digested
with NheI, to create the pCMV44tertluc, pCMV100tertluc
and pCMV200tertluc constructs, respectively. The same
inserts were subcloned into the pTERTtertluc and the
pCDKN2Atertluc vectors to create the plasmids pTERT44ter-
tluc, pTERT100tertluc, pTERT200tertluc, pCDKN2A44ter-
tluc, pCDKN2A100tertluc and pCDKN2A200tertluc.
All these constructs have been confirmed by sequencing on
an ABI Prism 3100 sequencer (Applied Biosystems, Foster
City, CA).
Transient transfection and luciferase assay
Cells were seeded at a concentration of 300 000/3.8 cm2
for HeLa, NCCIT, OVCAR-3, U2-OS and GM847, and
100 000 cells/3.8 cm2 for HLF, HLF/hTERT and BJ, and cul-
tured overnight. Transient transfection of luciferase reporter
plasmids were carried out using lipofectin plus reagent for
HeLa, or LipofectAMINE for all other cell lines according to
the manufacturer’s protocols (Invitrogen, Basel, Switzerland).
All experiments were performed at least in triplicate. The
Renilla luciferase reporter vector (Promega, Madison, WI)
was co-transfected as an internal control for transfection effi-
ciency. Briefly, HeLa cells were exposed to a transfection
Nucleic Acids Research, 2005, Vol. 33, No. 21 6851
mixture containing 0.6 mg of luciferase reporter plasmids and
0.6 mg of internal control vector mix with 0.75 ml of lipofectine
for 3 h at 37C. Then, 1 ml of growth media supplemented
with 15% HI-FBS was added to the cells. The cells were
harvested 48 h after transfection. The other cell lines were
exposed to a transfection mixture containing 0.8 mg of luci-
ferase reporter plasmids and 0.8 mg of internal control vector
with 4 ml of lipofectAMINE for 5 h at 37C. Luciferase
assays were performed using the Dual-Luciferase Reporter
Assay System (Promega, Madison, WI). To compare the
results, the mean values of relative luciferase activity
obtained in the three experiments were used. The transcription
levels detected with the different constructs were compared
with the transcription level of the pGL3-control vector
containing the firefly luciferase gene under the control of
the SV40 early promoter and to the transcription level of
the pGL3 basic vector, a promoterless and enhancerless
luciferase vector.
Small interfering RNA (siRNA) transfection assay
Cells were seeded in 12-well plates at a concentration of
100 000/well for HeLa and 30 000 cells/well for BJ. The
cells were then cultured overnight. Co-transfections of siRNA
(50 nM) and plasmids (1 mg/well) were carried out in duplicate
using the JetSI-ENDO Cationic Transfection reagent
(4 ml/well) (Polyplus-transfection, Illkirch, France) according
to the manufacturer’s instructions. siRNA for CTCF 50-(UUG-
GUUCGGCAUCGUCGUU)dTT-30 was synthesized by
Qiagen-Xeragon (Germantown, MD). siRNAs for silencing-
control and for luciferase pGL3 were provided in the jetsilen-
cing control kit Luciferase pGL3 (Polyplus-transfection, Ill-
kirch, France). BJ cells, transfected only with siRNAs, were
harvested 48 h post transfection. The hTERT gene expression
was analyzed by RT–PCR and TRAP assay (43). HeLa cells
were co-transfected with siRNAs and either pTERT/297
or pTERT297/ex1, and luciferase assays were performed
48 h later.
RNA extraction and hTERT RT–PCR analysis
RNAs were extracted from cells transfected with siRNA, using
the TRIzol LS Reagent (Invitrogen, Basel, Switzerland).
Platinum quantitative RT–PCR Thermoscript one-step system
(Invitrogen) was used to amplify the hTERT mRNA using the
primers LT5 50-CGGAAGAGTGTCTGGAGCAA-30 (exon3)
and LT6 50-GGATGAAGCGGAGTCTGGA-30 (exon4), with
co-amplification of b-actin with the primers FW 50-AGGC-
CAACCGCGAGAAGATGA-30 and REV 50-GCCGTGG-
TGGTGAAGCTGTAG-30. The hTERT splicing variants
(a, b, a/b and FL) were determined by RT–PCR using the
primers FW-SP 50-GCCTGAGCTGTACTTTGTCAA-30 and
REV-SP 50-CGCAAACAGCTTGTTCTCCATGTC-30. The
FL variant was obtained with the primers FW-FL 50-CGCCT-
GAGCTGTACTTTGTCA-30 and REV-FL 50-CGGCTGG-
AGGTCTGTCAAG-30. RT–PCR products were analyzed
on 2% agarose gel. The FL and the b-spliced variant
fragments were extracted from the gel, purified with the
QIAquick gel extraction kit (Qiagen) and sequenced on an
ABI Prism 3100 sequencer (Applied Biosystems, Foster
City, CA).
Electrophoretic mobility shift assay (EMSA)
and dimethyl sulfate (DMS)-methylation
interference analysis
Different fragments of the hTERT promoter and proximal
exonic region were synthesized by PCR with the following






CGGCCTCCCTGAC-30. EMSA was performed as described
earlier (44). Briefly, PCR fragments were end-labeled using
32P-g-ATP and T4 polynucleotide kinase (New England
Biolabs). Protein–DNA complexes were allowed to form by
incubation for 30 min at ambient temperature in phosphate-
buffered saline (PBS) with 5 mM MgCl2, 0.1 mM ZnSO4,
1 mM DTT, 0.1% Nonidet P-40, 10% glycerol and
poly(dI–dC). Full-length CTCF and the Zn-fingers DNA-
binding domain of CTCF were translated in vitro using the
TnT kit (Promega, WI). Protein–DNA complexes were
resolved from unbound DNA probe in 5% native polyacryl-
amide gel in 0.5· TBE.
DMS-methylation interference analysis was performed
with full-length CTCF and the F1 and F3 PCR fragments
amplified by sense and antisense primers, F1-FW and F1-
RW, and F3-FW and F3-RV, respectively. Fragments were
subcloned to pCR2.1-TOPO vector (Invitrogen, Carlsbad,
CA) and sequence verified. Then, fragments containing the
region F1 or F3 were amplified by PCR using 32P 50 end-
labeled M13 forward or reverse primers in order to obtain
labeling on either the sense or the antisense strand. Methyla-
tion of guanine residues was done by DMS, using conditions
that modified only a single nucleotide per molecule fragment.
After binding to high concentrations of CTCF, EMSA was
performed. Free and bound probes were cut and extracted
from the gel, cleaved at modified nucleotides with piperid-
ine and then analyzed on a sequencing gel as described
previously (45).
The 122 bp F1wt and 103 bp F3wt fragments, containing
the CTCF-binding sites located in the first and second exon
of hTERT, respectively, were synthesized by PCR. Mutant
fragments F1mut and F3mut were prepared by mutagenesis
using synthetic oligonucleotides of 122 and 103 bp, res-
pectively, with subsequent PCR amplification with the
same primers as for wild-type fragments. Mutations were
confirmed by sequencing of the PCR fragments. Eleven
and five bases were changed in the F1 and F3 fragments,
respectively.
Chromatin immunoprecipitaion (ChIP) assay
To crosslink proteins to DNA, 12 ml of a 1% formaldehyde
solution in culture medium was added to the cells cultured to
50% confluency, and the cells were incubated 15 min at room
temperature. Then, 1.3 ml of a 1.25 M glycine solution was
added to the medium to stop the reaction. After 5 min, the cells
were centrifuged and resuspended in 10 ml of ice-cold PBS
containing protease inhibitors. One million cells were pelleted,
resuspended in 200 ml of SDS lysis buffer (1% SDS, 10 nM
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EDTA and 50 mM Tris–HCl, pH 8.1) and incubated on ice for
10 min. The lysate was sonicated to shear DNA. The chro-
matin solution was diluted in 1800 ml of the ChIP dilution
buffer (0.01% SDS; 1.1% Triton X-100; 1.2 mM EDTA;
16.7 mM Tris–HCl, pH 8.1; 167 mM NaCl; and protease
inhibitors) for further immunoprecipitation or stored at 4C
to be directly uncrosslinked and purified (DNA input fraction).
Magnetic beads, 80 ml (Dynabeads M-280 Sheep anti-
Rabbit IgG, Dynal biotech, Oslo, Norway) were washed
three times with 1 ml of blocking solution (1· PBS;
5 mg/ml BSA; 3% of a 1 mg/ml sonicated herring sperm
DNA solution; and protease inhibitors). Half of the beads
were suspended in 250 ml of the blocking solution either
with 2 mg of the rabbit polyclonal anti-CTCF antibody
(Upstate biotechnology, Lake Placid, NY) or without anti-
body, and rocked for 4 h at 4C. The beads were then washed
three times with 1 ml of the blocking solution, and then, added
to 1 ml of the diluted chromatin solution and incubated
overnight at 4C. They were then washed twice with 500 ml
of each washing solutions: low salt solution (0.1% SDS;
10% Triton X-100; 2 mM EDTA; 20 mM Tris–HCl, pH
8.1; and 150 mM NaCl), high salt solution (0.1% SDS;
10% Triton X-100; 2 mM EDTA; 20 mM Tris–HCl, pH
8.1; and 500 mM NaCl), LiCl solution (0.25 M LiCl; 1%
NP40; 1% deoxycholate; 1 mM EDTA; and 10 mM Tris–
HCl, pH 8.1) and TE (10 mM Tris–HCl; and 1 mM EDTA,
pH 8.0). The eluate was then resuspended in 50 ml of the
elution buffer (1% SDS; and 0.1 M NaHCO3) and incubated
10 min at 65C. To reverse protein–DNA crosslinks, eluates
were incubated at 65C for 4 h in 120 ml of a solution con-
taining 1% of SDS and 0.3 M NaCl. Then 180 ml of ATL
buffer (Qiagen, Basel, Switzerland) and 20 ml of proteinase K
were added to samples, and incubation was performed
overnight at 55C. Immunoprecipitated DNA was recovered
by extraction with the DNeasy tissue kit (Qiagen, Basel,
Switzerland). Purified DNA was analyzed by PCR with
specific primers for the amplification of either the first exon
of the hTERT gene to generate a 299 bp fragment (ChIP-
ex-FW 50-CCCTGCTGCGCAGCCACTAC-30 and ChIP-ex-
RV 50-TCGGGCCACCAGCTCCTTCA-30) or the H19
gene as a control (ChIP-H19 FW 50-CTCCTTCGGTCTC-
ACCGCCTGGAT-30 and ChIP-H19-RV 50-CCTTAGACG-
GAGTCGGAGCTG-30). PCR products were analyzed on
2% agarose gel.
Western blot analysis
Approximately 40 mg of total cell extracts prepared
from transfected cells in 5· Passive lysis buffer (Promega)
were boiled 5 min in loading buffer (125 mmol/l Tris–HCl,
pH 6.8, 40 g/l SDS, 200 g/l glycerol and 0.05 g/l bromphenol
blue) for 5 min and then loaded onto a 8% SDS–PAGE.
After electrophoresis, proteins were transferred onto
PVDF membrane. Immunodetection was performed using a
rabbit polyclonal anti-CTCF antibody (Upstate biotechnology,
Lake Placid, NY). Protein bands were visualized using
ECL-Plus kit (Amersham Pharmacia Biotech, Switzerland)
according to the manufacturer’s instructions. Mouse
antibody against b-actin (AC-15, Sigma-Aldrich, Switzerland)
in western blot was used as a control for protein
concentration.
RESULTS
The inhibitory effect of the proximal exonic region
of the hTERT gene is cell type-independent
In earlier studies on HeLa cells we found the proximal exonic
region to repress hTERT expression (41). We further studied
the effect of this regulatory region in telomerase-positive,
-negative and immortalized cells. The intronic region was
omitted, to avoid transcript variation resulting from alternative
splicing (41). As shown in Figure 1, the hTERT minimal pro-
moter exhibited a high level of transcriptional activity in 4
telomerase-positive tumor cell lines, in U2-OS and in GM847
cells (30–120%). In contrast, the promoter activity was signi-
ficantly lower in the normal telomerase-negative and in the
HLF/hTERT cells (12–18%). A markedly decreased activity
(7-fold in the HeLa and SW480, 3-fold in OVCAR-3 and
NCCIT, 16-fold in U2-OS and GM847 cells) was observed
when the first exon of the hTERT gene was included in the
reporter construct (Figure 1). In telomerase-negative and HLF/
hTERT immortalized cells, transcriptional activity was no
longer detected. These results demonstrate that the inhibitory
effect of the hTERT proximal exonic region is not cell
type-dependent.
The proximal exonic region of the hTERT gene
has a repressor effect on different promoters
To determine if the repressor effect of the proximal exonic
region is promoter specific, constructs containing this region
but directed either by the CMV or CDKN2A promoters were
transiently transfected into the following cell lines: HeLa,
GM847, HLF/hTERT and BJ cells. In HeLa and GM847
cells, the CMV promoter had a 15- and 53-fold higher activity
than the reference SV40 promoter, whereas the transcriptional
activity of hTERT and CDKN2A promoters was significantly
lower (Figure 2A). Relative to the SV40 promoter, the activity
of the CDKN2A promoter was higher in GM847 cells than in
HeLa cells, with levels increased 1.3- and 0.4-fold respect-
ively. In HLF/hTERT and BJ cells, the activity of the CMV
promoter was 4.1- and 2.6-fold higher than the SV40 promoter
(Figure 2A). These results show that each promoter is more
active in HeLa and GM847 than in the two other cell lines. We
also studied the effect of the proximal exonic region of hTERT
(first exon and 885 bp of the second exon) on the transcrip-
tional activity of these promoters (Figure 2B). In HeLa and
GM847 cells, the exonic region reduced CMV promoter activ-
ity by 8.1- and 15.4-fold, respectively. In the same cells,
CDKN2A promoter activity was reduced 5- and 23-fold and
hTERT promoter activity was reduced 10- and 9.4-fold. In
HLF/hTERT and BJ, the activity of the CDKN2A and
hTERT promoters was barely detectable, while the CMV pro-
moter was 33- and 22-fold decreased (Figure 2B). Therefore,
the strong repressor effect of the proximal exonic region of the
hTERT gene is both promoter- and cell type-independent.
The level of inhibition by the exonic hTERT
region is dependent on the distance between the
promoter and the exonic region
In order to further analyze the repressive effect of the proximal
exonic region of the hTERT gene, short plasmid sequences
(44, 100 and 200 bp) were inserted between the promoter and
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the exonic region. Relative to the constructions without insert,
a 2.8-fold decrease in promoter activity was observed after
insertion of the 44 bp fragment, a 1.6-fold reduction with the
introduction of the 100 bp fragment, while no decrease or even
a slight increase in expression was detected when the 200 bp
fragment was inserted (Table 1). The same pattern was
observed for HeLa and GM847 cells, regardless of which
promoter was used. In HLF/hTERT and BJ cells, similar
observations were made for the CMV promoter. For the
CDKN2A and hTERT promoters, transcriptional activity was
undetectable. We conclude that increasing the distance
between the promoter and the exonic region, by either 44
or 100 bp, leads to significantly stronger inhibition of tran-
scriptional activity by the hTERT proximal exonic region. A
return to a basal level of transcriptional activity was observed
when the 200 bp sequence was inserted, which could suggest a
link with the nucleosome positioning.
CTCF interacts in vitro and in vivo with the
hTERT proximal exonic region
CTCF, a ubiquitously expressed 11 zinc finger nuclear
phosphoprotein, binds to GC-rich sequences and inhibits
transcription when located downstream of a transcriptional
start site (46). Since the exonic region of the hTERT gene
is GC-rich and its repressor effect is not cell type-specific,
we considered CTCF a plausible candidate for involvement in
the inhibition of hTERT expression. (47). In vitro binding of
fragments of the proximal exonic region to full-length CTCF
protein was tested by EMSA (Figure 3B). The100 to +133 bp
(fragment F1, located in the exon 1) and +348 to +597 bp
(fragment F3, located in the exon 2) sequences of the hTERT
gene showed retarded migration (Figures 3A and 3B). Mobility
shifts were not observed with two other regions tested. These
results demonstrate that CTCF binds in vitro to the first two
exons of the hTERT gene. CTCF-binding specificity was fur-
ther confirmed by competition assay with F2 chicken globin
insulator (48). Both F1 and F3 fragments were successfully
competed by a strong CTCF-binding site and 100-fold excess
of competitor completely abrogate CTCF binding to hTERT
(Figure 3C).
To determine if CTCF binds in vivo to this region, we
performed ChIP assays. Two telomerase-positive cell lines
(HeLa and SW480), one immortalized cell line (HLF/
hTERT) and one telomerase-negative cell line (BJ) were
tested. The experiments were carried out with and without
CTCF-specific antibody for the immunoprecipitation. Then,
PCRs were performed at different number of cycles to amplify
Figure 1. Transcriptional activity of the hTERT promoter in different cell lines. (A) Schematic representation of the luciferase reporter plasmids pTERT-297
and pTERT-297/ex1. (B) These two reporters were transfected into four telomerase-positive cancer cell lines (HeLa, SW480, OVCAR-3 and NCCIT), one
telomerase-negative sarcoma line (U2-OS), and two normal telomerase-negative (BJ and HLF), and two immortalized (GM847 immortalized in vitro with
SV40 and HLF/hTERT that exogenously expressed hTERT) fibroblast cell lines. For all experiments, 100% of the luciferase activity is represented by the
pGL3-control vector activity containing the SV40 enhancer/promoter.
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Figure 2. Transcriptional activity of different promoters in HeLa, GM847, HLF/hTERT and BJ cell lines. (A) Activities of luciferase reporter plasmids containing the
CMV, CDKN2A and hTERT promoter in these cell lines. (B) Activities of luciferase reporter plasmids containing the hTERT exon 1 and 885 bp of the exon 2, without
the first intron, driven by the CMV, CDKN2A and hTERT promoter in these cell lines. For all experiments, 100% of the luciferase activity is represented by the
pGL3-control vector activity containing the SV40 enhancer/promoter.
Table 1. Relative luciferase activity after insertion of a plasmid sequence between a promoter and the hTERT proximal exonic region
Transfected plasmid Cell lines
HeLa GM847 HLF/hTERT BJ
A B A B A B A B
PTERT tertluc 8 100 12.6 100 NS — NS —
PTERT 44 tertluc 2.5 31 9.5 75 NS — NS —
PTERT 100 tertluc 4.7 59 6.6 52 NS — NS —
PTERT 200 luc 10.9 136 7.6 60 NS — NS —
pCDKN2A tertluc 6.7 100 5.6 100 NS — NS —
pCDKN2A 44 tertluc 2.13 30 2.2 39 NS — NS —
pCDKN2A 100 tertluc 4.2 60 3.1 55 NS — NS -
pCDKN2A 200 tertluc 6.9 100 2.3 40 NS — NS —
pCMV tertluc 193 100 350 100 12.5 100 7.1 100
pCMV 44 tertluc 75 40 136 35 3.1 25 3.55 50
pCMV 100 tertluc 150 80 277 71 5.4 43 6.67 94
pCMV 200 tertluc 250 134 600 150 13 104 7.17 101
A, % of luciferase activity relative to the SV40 early promoter (100%). Representative experiment of at least three independent transfections.
B, % of luciferase activity relative to the plasmid without insertion (100%).
NS, non-significant value, at the background level.
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CTCF-hTERT exon 1 site and H19 ICR4 site, which was used
as a positive control (44). PCRs were performed at conditions
in which the samples from controls without antibody always
showed negligible levels of background amplification. Amp-
lification of H19 ICR4 fragment can be seen in all DNA
fractions obtained with CTCF antibodies but not in negative
controls suggesting the ChIP assay was very specific. In con-
trast to the H19 ICR4, the hTERT first exon fragment was
found only in immunoprecipitated DNA from BJ and HLF/
hTERT cells (Figure 3D). These results indicate that CTCF
binds in vivo to the first exon of hTERT in BJ normal cells, as
well as in HLF/hTERT that do not express endogenous
hTERT, but not in telomerase-positive ones.
A DMS-methylation interference assay was used to deter-
mine potential contact guanine nucleotides recognized by
CTCF in the first two exons of the hTERT gene (Figure 4A
and B). CTCF-contacting guanines were located within the
DNA sequence from positions +4 to +39 and +422 to +440
downstream from the ATG translational start site. These
CTCF recognition sequences are GC-rich (83% for exon 1
and 100% for exon 2) and both contain CpG sites. To confirm
that contact guanines were correctly identified, we performed
site-directed mutagenesis within the F1 and F3 regions. Con-
tact guanines, marked by black dots on Figure 4A and B, were
substituted by adenines. EMSA comparison of wild-type
(F1wt and F3wt) and mutant (F1mut and F3mut) fragments
showed at least 90% reduction of the CTCF binding upon
mutation of part of the CTCF-contact guanines in F1 and
F3 (Figure 4C and D, respectively). The F2 fragment also
contained the binding sequence +422 to +440, but did not
exhibit retarded migration by EMSA (Figure 3B). This
might be due to location of the CTCF-binding site at the
extremity of the F2 fragment.
Binding of CTCF represses hTERT transcription
To determine if CTCF binding to the hTERT exon 1 is respons-
ible for the hTERT transcriptional inhibition, we examined the
effect of CTCF depletion with siRNA against CTCF. siRNA
activity was examined by co-transfection of HeLa cells with
luciferase expressing constructs pTERT–297 or pTERT–297/
ex1. Western blot analysis of cell lysates showed a dramatic
reduction of CTCF expression upon co-transfection of the
siRNA, but not cells transfected with a control siRNA
(Figure 5B). Consistent with our proposed role for CTCF as
a negative regulator of hTERT expression, co-transfection of
the pTERT–297/ex1 construct (promoter and first exon of
hTERT) with CTCF siRNA resulted in a 3-fold increase in
exogenous hTERT promoter activity, when compared with
cells co-transfected with a control siRNA (Figure 5A).
To provide additional evidence for the role of CTCF
as a repressor of hTERT gene expression, we transfected
CTCF siRNA in BJ, a telomerase-negative human
non-immortalized fibroblast. A strong decrease of CTCF
Figure 3. In vitro and in vivo interactions of CTCF with hTERT gene. (A) Schematic localization in the exons 1 and 2 of the hTERT gen of the PCR fragments used in
EMSA (the ATG is considered as +1). (B) EMSA was carried out with either control lysate (empty), lysate containing the 11 Zn-fingers of CTCF DNA-binding
domain (11ZF), or lysate containing the in vitro translated full-length CTCF (FLCTCF). The positions of the bound CTCF–DNA complexes, containing either the
11ZF domain or the FLCTCF, are indicated on the left by B-11ZF and B-FLCTCF, respectively. Free DNA probe (F) is also indicated. (C) Competition assay of
CTCF 11ZF using radioactive probes of F1 and F3 hTERT fragments and excess of cold F2 chicken globin insulator. L is in vitro translated luciferase and was used as a
negative control. Lanes covered with black triangle on top are 0-, 10- and 100-fold molar excess of competitor, respectively. Bound and free bands are indicated as in
(B). (D) ChIP assay using anti-CTCF antibody on two telomerase-positive cell lines (HeLa and SW480), one immortalized cell line (HLF/hTERT) and one
telomerase-negative cell line (BJ). PCR amplification of the test fragments (hTERT exon1 and H19) using as template DNA input fraction and DNA recovered from
immunoprecipitated fractions bound (plus) versus unbound (minus) by the anti-CTCF antibody.
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level was observed by western blotting after 48 h transfection
(Figure 6D). The hTERT messenger was detected in the extract
of BJ cells treated with siRNA for CTCF (Figure 6), and this
with three different sets of primers, which amplify full-length
(FL) hTERT mRNA and the a deletion, or the four different
forms in the same time (FL, a-, b- and a/b-deletions). Each
amplification was sequenced, confirming the presence of FL
and b-deletion forms of the hTERT mRNA. Nevertheless, no
positive TRAP assay was obtained in these conditions (data
not shown).
DISCUSSION
In a previous study, we detected a repressor effect of the
proximal exonic region (first two exons) of the hTERT gene
on its transcription (41). To better understand the mechanism
involved and to identify a potential repressor, we further char-
acterized the effects of this region of the hTERT gene.
Reporter gene constructs, composed of the hTERT minimal
core promoter with or without the exonic region, were tran-
siently transfected in normal telomerase-negative cells (BJ
and HLF), telomerase-negative sarcoma cells (U2-OS),
telomerase-positive cancer cells (HeLa, SW480; NCCIT
and OVCAR-3) and immortalized cell lines (telomerase-
negative GM847 and telomerase-positive HLF/hTERT). The
transcriptional activity of the hTERT core promoter was
significantly higher in telomerase-postive cancer cells than
in normal cells, very high in telomerase-negative GM847,
but weak in telomerase-positive HLF/hTERT. Transcriptional
activity of the hTERT minimal promoter was significantly
up-regulated in GM847 cells, obtained through transfection
with the SV40 large T-antigen, and immortalized through
the alternative lengthening telomere (49), in contrast to
HLF/hTERT cell line, which was obtained by infection of
primary fibroblast HLF cells with a MSCV-hTERT retrovirus.
HLF/hTERT cells express high levels of exogenous hTERT,
but the extension of life span does not change the phenotypic
properties of the cells because telomerase, unlike oncogenes,
does not cause growth deregulation (50). This could explain
why, in transient transfection experiments, we did not
observe transcriptional activation of the hTERT minimal
core promoter in HLF/hTERT cells, as occurred in tumor
and transformed cells. Thus, the presence of hTERT protein
or telomerase complex does not itself activate hTERT gene
transcription.
The addition of the proximal exonic region of hTERT down-
stream of the hTERT minimal promoter strongly reduced
promoter transcriptional activity in all cell lines tested.
Furthermore, this exonic region significantly inhibited the
transcriptional activity of the CMV and CDKN2A promoters,
regardless of the cell type. Therefore, the repressor effect of
the hTERT exonic region is not cell- or promoter-dependent.
The decrease in the transcriptional promoter activity in pres-
ence of the hTERT exonic region was higher in HLF/hTERT or
BJ cells than in HeLa or GM847 cells.
Figure 4. Identification of contact guanines specifically recognized by CTCF in the proximal exonic region of the hTERT gene. (A) DMS-methylation interference
analysis was carried out with the hTERT F1 fragment. Top (U) and bottom (L) strands are shown respectively. Bound (B) and free (F) probes are indicated on top of
each lane. Contact guanines are indicated in boldface. Guanines substituted for adenines in site-directed mutagenesis are indicated by black dots (B) DMS-
methylation interference analysis was carried out with the hTERT F3 fragment. All labels are as in (A). Guanines substituted for adenines in site-directed mutagenesis
are indicated by black dots. Eleven and five bases were changed in the F1 and F3 fragments, respectively. (C) EMSA of the wt (F1wt) and mutant (F1mut) fragments
F1, located in the first exon of the hTERT gene. (D) EMSA of the wt (F3wt) and mutant (F3mut) fragments F3, located in the second exon of the hTERT gene.
Luciferase control (Luc) and DNA-binding domain of CTCF (11ZF) were used in the assay. Free (F) and bound (B) probes are indicated.
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Sequence insertion was used to show how structural and
regulatory phenomena could involve nucleosome positioning
(51,52). Insertion of DNA sequences of 44 or 100 bp between a
promoter and the hTERT exonic region resulted in reduced
transcriptional expression, whereas a relatively constant level
of transcription was observed with spacer DNAs of 200 bp.
Thus, proper arrangement of nucleosome positioning within
the hTERT exonic region might inoculate the activity, and
perhaps accessibility, of the presumed repressor(s). Another
explanation for this observation could be that the repressor(s)
forms a bulky complex, which physically interferes with the
RNA polymerase II complex from the hTERT promoter. As a
function of the spatial configuration of these two large com-
plexes, this disturbance might be more or less pronounced.
CTCF was considered to be a good candidate for hTERT
transcriptional inhibition: CTCF is expressed in almost all cell
types, binds GC-rich sequences, represses transcriptional
activity when it is localized downstream of a transcriptional
start site and its activity depends on the chromatin structure
(44–46,53). We hypothesized that CTCF might be the
repressor involved. EMSA showed that CTCF binds to two
distinct sequences in exons 1 and 2 of hTERT. The methylation
interference experiment permitted the identification of CTCF-
binding sequences within the hTERT first exon at +4 to +39
positions and within the hTERT second exon at +422 to +440
positions (relative to the ATG translational start codon). Muta-
tions within these core sequences eliminated binding of CTCF,
confirming the identity of the two CTCF-binding sites. More-
over, as one can see in Figure 4A and B, single contact guanine
modification had a relatively low impact on CTCF binding,
suggesting some evolutionary pressure to keep the CTCF-
binding sites present regardless of stochastic point mutations.
In the case of the site F1, within the first exon of hTERT, we
had to substitute 11 contact guanines in order to eliminate
Figure 5. Depletion of CTCF by siRNA results in the relief of inhibition of
hTERT promoter by the hTERT exonic region. (A) Luciferase reporter plasmids
containing the hTERT minimal promoter, with or without the proximal exonic
region, are co-transfected into HeLa cells with either unrelated siRNA (control
siRNA), or CTCF siRNA or luciferase siRNA. In each experiment, the activity
is calculated considering the activity of hTERT promoter as 100%. pTERT-297,
minimal hTERT promoter; pTERT-297/ex1, minimal promoter and first exon of
the hTERT gene. (B) Western blot showing the decrease of CTCF protein in
cells treated with the specific siRNA for CTCF. b-Actin was used as internal
control to normalize the total protein amount.
Figure 6. Depletion of CTCF by siRNA results in transcriptional activation of
hTERT in telomerase-negative cells. (A) RT–PCR of hTERT from extracted
RNA of HeLa (telomerase-postive) and BJ (telomerase-negative) cells treated
with either control siRNA (minus) or CTCF siRNA (plus). RT–PCR was
performed using primer pair LT5 and LT6 to amplify a 145 bp segment common
to all hTERT transcripts. (B) Expression of spliced variants of hTERT mRNA.
The positions of the full-length (457 bp),a-spliced (421 bp), b-spliced (275 bp)
and a+b-spliced (239 bp) variants are indicated on the right. (C) Amplification
of FL and a-spliced variant only. (D) Western blot showing the decrease of
CTCF protein in cells treated with the specific siRNA for CTCF. b-Actin was
used as internal control to normalize the total protein amount.
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CTCF binding to the site, which is so far unprecedented.
Interestingly, and consistent with the description of some
other CTCF-binding sites (54), most of the CTCF-contact
nucleotides were located on a single DNA strand.
Many contact guanines are part of CpG sites suggesting that
CTCF binding might be regulated by DNA methylation. ChIP
assays confirmed that CTCF binds to the first exon of hTERT in
BJ and HLF/hTERT cells in which the endogenous hTERT
gene is not expressed, but not in HeLa and SW480 cells which
express hTERT. Moreover, in HeLa cells, the reduction of
CTCF expression by RNA interference stimulated the tran-
scriptional activity of the reporter that contained the first exon
of hTERT. In BJ cells, siRNA against CTCF induced the
transcription of hTERT mRNA. These results show that
CTCF is involved in the hTERT transcriptional repression.
Human hTERT is the first gene implicated in immortality
that might be controlled by CTCF.
In addition to CTCF, several negative regulators of hTERT
transcription have been identified, including p53, WT-1,
Mad1, myeloid-specific zinc finger protein 2 (MZF-2), and
others (55). Overexpression of wild-type p53 in MCF-7
cells can downregulate hTERT mRNA expression, but inhibi-
tion of p53 activity does not reactivate hTERT expression (56).
WT-1 can inhibit hTERT transcription (30) and Mad1 can
regulate the ability of c-Myc to activate hTERT (57). Although
all these factors can negatively regulate hTERT, none of them
appear to be responsible for the downregulation of hTERT in
the majority of telomerase-negative cells. To our knowledge,
CTCF is the only known factor that can negatively regulate
hTERT transcription independently of the cell type. Indeed,
CTCF is one such factor that is highly conserved, ubiquitously
expressed, and possesses versatile regulatory functions (57).
CTCF is a DNA-binding protein that uses various combina-
tions of its 11 zinc fingers to recognize a variety of unrelated
DNA sequences (45). It plays a major role in transcriptional
activation of the APPB promoter (58), silencing of c-myc (45),
insulation of b-globin gene (48,59) and imprinting control of
the H19 region (44). Concerning the hTERT gene, CTCF binds
to a region located within the first two exons and just down-
stream the promoter. Silencing of hTERT could be the con-
sequence of either inhibition of the transcription–initiation
complex or blockage of transcription elongation.
Our results suggest a model in which CTCF participates in
key cellular mechanisms underlying immortality by select-
ively regulating hTERT gene expression. We postulate that,
in telomerase-negative normal cells, CTCF binds to the hTERT
proximal exonic region and thus blocks transcription. The fact
that the hTERT first exon sequences are hypermethylated in
telomerase-positive cells (60) could explain the failure of
CTCF to bind to these sequences.
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